Repligen Corporation (RGEN) - Total Assets
Based on the latest financial reports, Repligen Corporation (RGEN) holds total assets worth $2.92 Billion USD as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Explore RGEN cash flow to debt ratio to assess how comfortably operating cash covers total debt obligations.
Repligen Corporation - Total Assets Trend (1985–2024)
This chart illustrates how Repligen Corporation's total assets have evolved over time, based on quarterly financial data. See RGEN total equity for net asset value and shareholders' equity analysis.
Repligen Corporation - Asset Composition Analysis
Current Asset Composition (December 2024)
Repligen Corporation's total assets of $2.92 Billion consist of 37.7% current assets and 62.3% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 26.8% |
| Accounts Receivable | $134.12 Million | 4.7% |
| Inventory | $142.96 Million | 5.1% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $397.90 Million | 14.1% |
| Goodwill | $1.03 Billion | 36.4% |
Asset Composition Trend (1985–2024)
This chart illustrates how Repligen Corporation's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see RGEN company net worth.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Repligen Corporation's current assets represent 37.7% of total assets in 2024, a decrease from 68.9% in 1985.
- Cash Position: Cash and equivalents constituted 26.8% of total assets in 2024, down from 61.2% in 1985.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 50.0% of total assets, an increase from 0.0% in 1985.
- Asset Diversification: The largest asset category is goodwill at 36.4% of total assets.
Repligen Corporation Competitors by Total Assets
Key competitors of Repligen Corporation based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Autek China Inc
SHE:300595
|
China | CN¥6.40 Billion |
|
Zhejiang Gongdong Medical Technology Co Ltd
SHG:605369
|
China | CN¥2.19 Billion |
|
MEDIMI AB AK
F:79T
|
Germany | €1.70 Million |
|
I.Ceram SA
PA:ALICR
|
France | €3.91 Million |
|
Ansell Ltd
AU:ANN
|
Australia | AU$3.33 Billion |
|
Nanosonics Ltd
AU:NAN
|
Australia | AU$279.25 Million |
|
SDI Ltd
AU:SDI
|
Australia | AU$135.84 Million |
|
Austco Healthcare Ltd
AU:AHC
|
Australia | AU$91.07 Million |
Repligen Corporation - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 8.36 | 10.44 | 2.83 |
| Quick Ratio | 7.14 | 8.76 | 2.53 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $965.35 Million | $1.02 Billion | $583.43 Million |
Repligen Corporation - Advanced Valuation Insights
This section examines the relationship between Repligen Corporation's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 3.58 |
| Latest Market Cap to Assets Ratio | 2.71 |
| Asset Growth Rate (YoY) | 0.2% |
| Total Assets | $2.83 Billion |
| Market Capitalization | $7.68 Billion USD |
Valuation Analysis
Premium Asset Valuation: The market values Repligen Corporation's assets at a significant premium (2.71x), suggesting investors see substantial growth potential or unique competitive advantages.
Positive Asset Growth: Repligen Corporation's assets grew by 0.2% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for Repligen Corporation (1985–2024)
The table below shows the annual total assets of Repligen Corporation from 1985 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $2.83 Billion | +0.19% |
| 2023-12-31 | $2.82 Billion | +11.57% |
| 2022-12-31 | $2.53 Billion | +7.35% |
| 2021-12-31 | $2.36 Billion | +23.94% |
| 2020-12-31 | $1.90 Billion | +35.91% |
| 2019-12-31 | $1.40 Billion | +904.03% |
| 2018-12-31 | $139.45 Million | +15.81% |
| 2017-12-31 | $120.41 Million | -58.32% |
| 2016-12-31 | $288.91 Million | +97.56% |
| 2015-12-31 | $146.24 Million | -323.52% |
| 2014-12-31 | $-65.43 Million | -155.14% |
| 2013-12-31 | $118.64 Million | +22.30% |
| 2012-12-31 | $97.01 Million | +27.48% |
| 2011-12-31 | $76.10 Million | +5.26% |
| 2010-12-31 | $72.29 Million | +1.22% |
| 2009-12-31 | $71.42 Million | -3.17% |
| 2008-12-31 | $73.75 Million | +7.14% |
| 2007-12-31 | $68.84 Million | +136.76% |
| 2006-12-31 | $29.08 Million | +1.67% |
| 2005-12-31 | $28.60 Million | +3.59% |
| 2004-12-31 | $27.61 Million | -6.78% |
| 2003-12-31 | $29.61 Million | -10.66% |
| 2002-12-31 | $33.15 Million | +13.87% |
| 2001-12-31 | $29.11 Million | -9.45% |
| 2000-12-31 | $32.15 Million | -11.41% |
| 1999-12-31 | $36.29 Million | +597.84% |
| 1998-12-31 | $5.20 Million | -8.77% |
| 1997-12-31 | $5.70 Million | -14.93% |
| 1996-12-31 | $6.70 Million | +17.54% |
| 1995-12-31 | $5.70 Million | -81.79% |
| 1994-12-31 | $31.30 Million | -23.84% |
| 1993-12-31 | $41.10 Million | -13.29% |
| 1992-12-31 | $47.40 Million | -19.66% |
| 1991-12-31 | $59.00 Million | +8.86% |
| 1990-12-31 | $54.20 Million | +43.39% |
| 1989-12-31 | $37.80 Million | +53.04% |
| 1988-12-31 | $24.70 Million | -10.18% |
| 1987-12-31 | $27.50 Million | +19.57% |
| 1986-12-31 | $23.00 Million | +123.30% |
| 1985-12-31 | $10.30 Million | -- |
About Repligen Corporation
Repligen Corporation, a life sciences company, develops and commercializes bioprocessing technologies and systems in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products. The company also provides chromatography products, including OPUS pre-pack… Read more